Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Ozempic made headlines. Now its maker faces stock crashes, CEO fallout, and fierce rivalry from Eli Lilly. Discover the trade behind the drama.

Scientists say they may have discovered a natural version of Ozempic that can replicate the effects of popular weight loss ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market ... less-expensive alternatives not approved ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Gillian Killiner RD, a specialist dietician at 121 Dietician, told The Independent: “Alternatives to GLP-1 medications like Ozempic, can be achieved using a holistic, evidence-based approach ...

Novo Nordisk, the company that makes Wegovy and Ozempic, is abruptly ousting its chief executive over concerns the firm is ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...